Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $80.2 million.

  • Collegium Pharmaceutical's Cost of Revenue rose 2828.96% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.9 million, marking a year-over-year increase of 4359.88%. This contributed to the annual value of $254.1 million for FY2024, which is 561.39% up from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Cost of Revenue of $80.2 million as of Q3 2025, which was up 2828.96% from $79.6 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Cost of Revenue registered a high of $83.7 million during Q4 2024, and its lowest value of $28.7 million during Q4 2021.
  • For the 5-year period, Collegium Pharmaceutical's Cost of Revenue averaged around $58.7 million, with its median value being $61.7 million (2023).
  • Per our database at Business Quant, Collegium Pharmaceutical's Cost of Revenue surged by 17820.53% in 2022 and then plummeted by 3096.04% in 2023.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Cost of Revenue stood at $28.7 million in 2021, then skyrocketed by 178.21% to $79.8 million in 2022, then tumbled by 30.96% to $55.1 million in 2023, then soared by 51.79% to $83.7 million in 2024, then fell by 4.15% to $80.2 million in 2025.
  • Its last three reported values are $80.2 million in Q3 2025, $79.6 million for Q2 2025, and $80.4 million during Q1 2025.